Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension are rare and life-threatening diseases. Adempas® has shown to be effective and well tolerated in both indications, in previous controlled studies. Adempas® can be freely prescribed for the treatment of patients with two types of pulmonary hypertension.
In accordance with the regulatory requirements, a registry, the EXPERT registry, has been designed to collect information about the long-term safety of Adempas® in real clinical practice outside the regulated environment of a controlled clinical study. The EXPERT registry is a global, multicenter, prospective, uncontrolled, non-interventional cohort study documenting data from patients with Pulmonary Hypertension treated with Adempas®.
The centre Hospitalier de Luxembourg is involved and CIEC-LIH is actively assisting and supporting physicians involved in this trial. The approximate total number of patients is 900; 4-5 patients in Luxembourg. The study population will consist on patients who have been prescribed Adempas® for a medically appropriate use. Indications and contraindications according to the local market authorization should be considered.
Additional information on this trial is available on our website under following link www.luxclin.lu/Studies/Details/?c=STP1711YHA
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
